Celcuity, Inc.
Industry Group: Pharmaceuticals
Country/Region: United States of America
Identifier: NAS:CELC
Celcuity Inc is a clinical-stage biotechnology company pursuing development for oncology. The Company’s lead therapeutic candidate is gedatolisib, a potent pan-PI3K and mTOR inhibitor. Its mechanism of action and pharmacokinetic properties are highly differentiated from other currently approved and investigational therapies that target PI3K or mTOR alone or together. A Phase 3 clinical trial, VIKTORIA-1, evaluating gedatolisib in combination with fulvestrant with or without palbociclib in patients with HR+/HER2- advanced breast cancer is currently enrolling patients.
ESG Risk Rating
Ranking
Industry Group (1st = lowest risk)
Pharmaceuticals 385 out of 850
Universe
Global Universe 9448 out of 15081
What are the ESG Risk Ratings?
Notice: The information is provided as is, for informational, non-commercial purposes only, does not constitute investment advice and is subject to conditions available in our Legal Disclaimer. They are not directed to, or intended for distribution to or use by India-based clients or users and their distribution to Indian resident individuals or entities is not permitted. Usage of this information is not permitted in any way, unless otherwise agreed in writing. By way of exception, usage of this information is permitted to the rated subject, limited to a single reference to the score on the rated subject’s sustainability webpage or CSR report, mentioning Sustainalytics as a source. For referencing Sustainalytics please consult the Company Guide.
Industry Comparison
Company | ESG Risk Rating | Industry Rank |
---|---|---|
CK Life Sciences International (Holdings), Inc. |
23.2
Medium
|
146 out of 850 |
Pharming Group NV |
25.4
Medium
|
222 out of 850 |
Terns Pharmaceuticals, Inc. |
26.2
Medium
|
264 out of 850 |
Celcuity, Inc. |
27.9
Medium
|
385 out of 850 |
Tango Therapeutics, Inc. |
29.6
Medium
|
470 out of 850 |
For corporate professionals interested in direct competitor insights
Sustainalytics' Peer Performance Insights gives an in-depth analysis of your company's ESG strengths and weaknesses compared to your competitors and industry performance. These insights can be used to identify areas of ESG improvement to help inform future management decisions that align with your organization's sustainability goals.
Our Approach to Calculating ESG Risk
The ESG Risk Ratings measure a company's exposure to industry-specific material ESG risks and how well a company is managing those risks.
Exposure
Exposure refers to the extent to which a company is exposed to different material ESG issues. Our exposure score takes into consideration subindustry and company-specific factors such as its business model.
Celcuity, Inc.'s Exposure is Medium
Management
Management refers to how well a company is managing its relevant ESG issues. Our management score assesses the robustness of a company's ESG programs, practices and policies.
Celcuity, Inc.'s Management of ESG Material Risk is Average